 | • レポートコード：GIR-107A12298 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、妊娠糖尿病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。妊娠糖尿病治療の種類別市場規模（インスリン、SGLT-2阻害薬、α-グルコシダーゼ阻害薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・妊娠糖尿病治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Biocon Limited、Eli Lilly、Novo Nordisk、Boehringer Ingelheim GmbH、Sanofi S.A.、Sun Pharmaceutical Industries Limited、Merck、Novartis、Adocia、Peptron、AstraZeneca plc、Pfizer, Inc、Takeda Pharmaceutical Company Ltd、Abbott、Antares Pharma、INJEX Pharma AG、Daiichi Sankyo ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：インスリン、SGLT-2阻害薬、α-グルコシダーゼ阻害薬、その他 ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局 ・妊娠糖尿病治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・妊娠糖尿病治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・妊娠糖尿病治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・妊娠糖尿病治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・妊娠糖尿病治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Gestational Diabetes Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Gestational Diabetes Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Gestational Diabetes Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Gestational Diabetes Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Insulin
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Others
Market segment by Application, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by players, this report covers
Biocon Limited
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Merck
Novartis
Adocia
Peptron
AstraZeneca plc
Pfizer, Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
INJEX Pharma AG
Daiichi Sankyo
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Gestational Diabetes Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Gestational Diabetes Treatment, with revenue, gross margin and global market share of Gestational Diabetes Treatment from 2019 to 2021.
Chapter 3, the Gestational Diabetes Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Gestational Diabetes Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Gestational Diabetes Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Gestational Diabetes Treatment
1.2 Classification of Gestational Diabetes Treatment by Type
1.2.1 Overview: Global Gestational Diabetes Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Gestational Diabetes Treatment Revenue Market Share by Type in 2020
1.2.3 Insulin
1.2.4 SGLT-2 Inhibitors
1.2.5 Alpha-glucosidase Inhibitors
1.2.6 Others
1.3 Global Gestational Diabetes Treatment Market by Application
1.3.1 Overview: Global Gestational Diabetes Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Gestational Diabetes Treatment Market Size & Forecast
1.5 Global Gestational Diabetes Treatment Market Size and Forecast by Region
1.5.1 Global Gestational Diabetes Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Gestational Diabetes Treatment Market Size by Region, (2016-2021)
1.5.3 North America Gestational Diabetes Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Gestational Diabetes Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Gestational Diabetes Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Gestational Diabetes Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Gestational Diabetes Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Gestational Diabetes Treatment Market Drivers
1.6.2 Gestational Diabetes Treatment Market Restraints
1.6.3 Gestational Diabetes Treatment Trends Analysis
2 Company Profiles
2.1 Biocon Limited
2.1.1 Biocon Limited Details
2.1.2 Biocon Limited Major Business
2.1.3 Biocon Limited Gestational Diabetes Treatment Product and Solutions
2.1.4 Biocon Limited Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Biocon Limited Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Gestational Diabetes Treatment Product and Solutions
2.2.4 Eli Lilly Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Eli Lilly Recent Developments and Future Plans
2.3 Novo Nordisk
2.3.1 Novo Nordisk Details
2.3.2 Novo Nordisk Major Business
2.3.3 Novo Nordisk Gestational Diabetes Treatment Product and Solutions
2.3.4 Novo Nordisk Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Novo Nordisk Recent Developments and Future Plans
2.4 Boehringer Ingelheim GmbH
2.4.1 Boehringer Ingelheim GmbH Details
2.4.2 Boehringer Ingelheim GmbH Major Business
2.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Product and Solutions
2.4.4 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.5 Sanofi S.A.
2.5.1 Sanofi S.A. Details
2.5.2 Sanofi S.A. Major Business
2.5.3 Sanofi S.A. Gestational Diabetes Treatment Product and Solutions
2.5.4 Sanofi S.A. Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Sanofi S.A. Recent Developments and Future Plans
2.6 Sun Pharmaceutical Industries Limited
2.6.1 Sun Pharmaceutical Industries Limited Details
2.6.2 Sun Pharmaceutical Industries Limited Major Business
2.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Product and Solutions
2.6.4 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Sun Pharmaceutical Industries Limited Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Gestational Diabetes Treatment Product and Solutions
2.7.4 Merck Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Gestational Diabetes Treatment Product and Solutions
2.8.4 Novartis Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Adocia
2.9.1 Adocia Details
2.9.2 Adocia Major Business
2.9.3 Adocia Gestational Diabetes Treatment Product and Solutions
2.9.4 Adocia Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Adocia Recent Developments and Future Plans
2.10 Peptron
2.10.1 Peptron Details
2.10.2 Peptron Major Business
2.10.3 Peptron Gestational Diabetes Treatment Product and Solutions
2.10.4 Peptron Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Peptron Recent Developments and Future Plans
2.11 AstraZeneca plc
2.11.1 AstraZeneca plc Details
2.11.2 AstraZeneca plc Major Business
2.11.3 AstraZeneca plc Gestational Diabetes Treatment Product and Solutions
2.11.4 AstraZeneca plc Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 AstraZeneca plc Recent Developments and Future Plans
2.12 Pfizer, Inc
2.12.1 Pfizer, Inc Details
2.12.2 Pfizer, Inc Major Business
2.12.3 Pfizer, Inc Gestational Diabetes Treatment Product and Solutions
2.12.4 Pfizer, Inc Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Pfizer, Inc Recent Developments and Future Plans
2.13 Takeda Pharmaceutical Company Ltd
2.13.1 Takeda Pharmaceutical Company Ltd Details
2.13.2 Takeda Pharmaceutical Company Ltd Major Business
2.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Product and Solutions
2.13.4 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Takeda Pharmaceutical Company Ltd Recent Developments and Future Plans
2.14 Abbott
2.14.1 Abbott Details
2.14.2 Abbott Major Business
2.14.3 Abbott Gestational Diabetes Treatment Product and Solutions
2.14.4 Abbott Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Abbott Recent Developments and Future Plans
2.15 Antares Pharma
2.15.1 Antares Pharma Details
2.15.2 Antares Pharma Major Business
2.15.3 Antares Pharma Gestational Diabetes Treatment Product and Solutions
2.15.4 Antares Pharma Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Antares Pharma Recent Developments and Future Plans
2.16 INJEX Pharma AG
2.16.1 INJEX Pharma AG Details
2.16.2 INJEX Pharma AG Major Business
2.16.3 INJEX Pharma AG Gestational Diabetes Treatment Product and Solutions
2.16.4 INJEX Pharma AG Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 INJEX Pharma AG Recent Developments and Future Plans
2.17 Daiichi Sankyo
2.17.1 Daiichi Sankyo Details
2.17.2 Daiichi Sankyo Major Business
2.17.3 Daiichi Sankyo Gestational Diabetes Treatment Product and Solutions
2.17.4 Daiichi Sankyo Gestational Diabetes Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Daiichi Sankyo Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Gestational Diabetes Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Gestational Diabetes Treatment Players Market Share
3.2.2 Top 10 Gestational Diabetes Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Gestational Diabetes Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Gestational Diabetes Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Gestational Diabetes Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Gestational Diabetes Treatment Revenue Market Share by Application (2016-2021)
5.2 Gestational Diabetes Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Gestational Diabetes Treatment Revenue by Type (2016-2026)
6.2 North America Gestational Diabetes Treatment Revenue by Application (2016-2026)
6.3 North America Gestational Diabetes Treatment Market Size by Country
6.3.1 North America Gestational Diabetes Treatment Revenue by Country (2016-2026)
6.3.2 United States Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Gestational Diabetes Treatment Revenue by Type (2016-2026)
7.2 Europe Gestational Diabetes Treatment Revenue by Application (2016-2026)
7.3 Europe Gestational Diabetes Treatment Market Size by Country
7.3.1 Europe Gestational Diabetes Treatment Revenue by Country (2016-2026)
7.3.2 Germany Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
7.3.3 France Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Gestational Diabetes Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Gestational Diabetes Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Gestational Diabetes Treatment Market Size by Region
8.3.1 Asia-Pacific Gestational Diabetes Treatment Revenue by Region (2016-2026)
8.3.2 China Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
8.3.5 India Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Gestational Diabetes Treatment Revenue by Type (2016-2026)
9.2 South America Gestational Diabetes Treatment Revenue by Application (2016-2026)
9.3 South America Gestational Diabetes Treatment Market Size by Country
9.3.1 South America Gestational Diabetes Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Gestational Diabetes Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Gestational Diabetes Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Gestational Diabetes Treatment Market Size by Country
10.3.1 Middle East & Africa Gestational Diabetes Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Gestational Diabetes Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Gestational Diabetes Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Gestational Diabetes Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Gestational Diabetes Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Gestational Diabetes Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Gestational Diabetes Treatment Revenue Market Share by Region (2021-2026)
Table 6. Biocon Limited Corporate Information, Head Office, and Major Competitors
Table 7. Biocon Limited Major Business
Table 8. Biocon Limited Gestational Diabetes Treatment Product and Solutions
Table 9. Biocon Limited Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 11. Eli Lilly Major Business
Table 12. Eli Lilly Gestational Diabetes Treatment Product and Solutions
Table 13. Eli Lilly Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 15. Novo Nordisk Major Business
Table 16. Novo Nordisk Gestational Diabetes Treatment Product and Solutions
Table 17. Novo Nordisk Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim GmbH Major Business
Table 20. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Product and Solutions
Table 21. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Sanofi S.A. Corporate Information, Head Office, and Major Competitors
Table 23. Sanofi S.A. Major Business
Table 24. Sanofi S.A. Gestational Diabetes Treatment Product and Solutions
Table 25. Sanofi S.A. Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Sun Pharmaceutical Industries Limited Corporate Information, Head Office, and Major Competitors
Table 27. Sun Pharmaceutical Industries Limited Major Business
Table 28. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Product and Solutions
Table 29. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Gestational Diabetes Treatment Product and Solutions
Table 33. Merck Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Gestational Diabetes Treatment Product and Solutions
Table 37. Novartis Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Adocia Corporate Information, Head Office, and Major Competitors
Table 39. Adocia Major Business
Table 40. Adocia Gestational Diabetes Treatment Product and Solutions
Table 41. Adocia Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Peptron Corporate Information, Head Office, and Major Competitors
Table 43. Peptron Major Business
Table 44. Peptron Gestational Diabetes Treatment Product and Solutions
Table 45. Peptron Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. AstraZeneca plc Corporate Information, Head Office, and Major Competitors
Table 47. AstraZeneca plc Major Business
Table 48. AstraZeneca plc Gestational Diabetes Treatment Product and Solutions
Table 49. AstraZeneca plc Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Pfizer, Inc Corporate Information, Head Office, and Major Competitors
Table 51. Pfizer, Inc Major Business
Table 52. Pfizer, Inc Gestational Diabetes Treatment Product and Solutions
Table 53. Pfizer, Inc Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Takeda Pharmaceutical Company Ltd Corporate Information, Head Office, and Major Competitors
Table 55. Takeda Pharmaceutical Company Ltd Major Business
Table 56. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Product and Solutions
Table 57. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Abbott Corporate Information, Head Office, and Major Competitors
Table 59. Abbott Major Business
Table 60. Abbott Gestational Diabetes Treatment Product and Solutions
Table 61. Abbott Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Antares Pharma Corporate Information, Head Office, and Major Competitors
Table 63. Antares Pharma Major Business
Table 64. Antares Pharma Gestational Diabetes Treatment Product and Solutions
Table 65. Antares Pharma Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. INJEX Pharma AG Corporate Information, Head Office, and Major Competitors
Table 67. INJEX Pharma AG Major Business
Table 68. INJEX Pharma AG Gestational Diabetes Treatment Product and Solutions
Table 69. INJEX Pharma AG Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Daiichi Sankyo Corporate Information, Head Office, and Major Competitors
Table 71. Daiichi Sankyo Major Business
Table 72. Daiichi Sankyo Gestational Diabetes Treatment Product and Solutions
Table 73. Daiichi Sankyo Gestational Diabetes Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Global Gestational Diabetes Treatment Revenue (USD Million) by Players (2019-2021)
Table 75. Global Gestational Diabetes Treatment Revenue Share by Players (2019-2021)
Table 76. Breakdown of Gestational Diabetes Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 77. Gestational Diabetes Treatment Players Head Office, Products and Services Provided
Table 78. Gestational Diabetes Treatment Mergers & Acquisitions in the Past Five Years
Table 79. Gestational Diabetes Treatment New Entrants and Expansion Plans
Table 80. Global Gestational Diabetes Treatment Revenue (USD Million) by Type (2016-2021)
Table 81. Global Gestational Diabetes Treatment Revenue Share by Type (2016-2021)
Table 82. Global Gestational Diabetes Treatment Revenue Forecast by Type (2021-2026)
Table 83. Global Gestational Diabetes Treatment Revenue by Application (2016-2021)
Table 84. Global Gestational Diabetes Treatment Revenue Forecast by Application (2021-2026)
Table 85. North America Gestational Diabetes Treatment Revenue by Type (2016-2021) & (USD Million)
Table 86. North America Gestational Diabetes Treatment Revenue by Type (2021-2026) & (USD Million)
Table 87. North America Gestational Diabetes Treatment Revenue by Application (2016-2021) & (USD Million)
Table 88. North America Gestational Diabetes Treatment Revenue by Application (2021-2026) & (USD Million)
Table 89. North America Gestational Diabetes Treatment Revenue by Country (2016-2021) & (USD Million)
Table 90. North America Gestational Diabetes Treatment Revenue by Country (2021-2026) & (USD Million)
Table 91. Europe Gestational Diabetes Treatment Revenue by Type (2016-2021) & (USD Million)
Table 92. Europe Gestational Diabetes Treatment Revenue by Type (2021-2026) & (USD Million)
Table 93. Europe Gestational Diabetes Treatment Revenue by Application (2016-2021) & (USD Million)
Table 94. Europe Gestational Diabetes Treatment Revenue by Application (2021-2026) & (USD Million)
Table 95. Europe Gestational Diabetes Treatment Revenue by Country (2016-2021) & (USD Million)
Table 96. Europe Gestational Diabetes Treatment Revenue by Country (2021-2026) & (USD Million)
Table 97. Asia-Pacific Gestational Diabetes Treatment Revenue by Type (2016-2021) & (USD Million)
Table 98. Asia-Pacific Gestational Diabetes Treatment Revenue by Type (2021-2026) & (USD Million)
Table 99. Asia-Pacific Gestational Diabetes Treatment Revenue by Application (2016-2021) & (USD Million)
Table 100. Asia-Pacific Gestational Diabetes Treatment Revenue by Application (2021-2026) & (USD Million)
Table 101. Asia-Pacific Gestational Diabetes Treatment Revenue by Region (2016-2021) & (USD Million)
Table 102. Asia-Pacific Gestational Diabetes Treatment Revenue by Region (2021-2026) & (USD Million)
Table 103. South America Gestational Diabetes Treatment Revenue by Type (2016-2021) & (USD Million)
Table 104. South America Gestational Diabetes Treatment Revenue by Type (2021-2026) & (USD Million)
Table 105. South America Gestational Diabetes Treatment Revenue by Application (2016-2021) & (USD Million)
Table 106. South America Gestational Diabetes Treatment Revenue by Application (2021-2026) & (USD Million)
Table 107. South America Gestational Diabetes Treatment Revenue by Country (2016-2021) & (USD Million)
Table 108. South America Gestational Diabetes Treatment Revenue by Country (2021-2026) & (USD Million)
Table 109. Middle East & Africa Gestational Diabetes Treatment Revenue by Type (2016-2021) & (USD Million)
Table 110. Middle East & Africa Gestational Diabetes Treatment Revenue by Type (2021-2026) & (USD Million)
Table 111. Middle East & Africa Gestational Diabetes Treatment Revenue by Application (2016-2021) & (USD Million)
Table 112. Middle East & Africa Gestational Diabetes Treatment Revenue by Application (2021-2026) & (USD Million)
Table 113. Middle East & Africa Gestational Diabetes Treatment Revenue by Country (2016-2021) & (USD Million)
Table 114. Middle East & Africa Gestational Diabetes Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Gestational Diabetes Treatment Picture
Figure 2. Global Gestational Diabetes Treatment Revenue Market Share by Type in 2020
Figure 3. Insulin
Figure 4. SGLT-2 Inhibitors
Figure 5. Alpha-glucosidase Inhibitors
Figure 6. Others
Figure 7. Gestational Diabetes Treatment Revenue Market Share by Application in 2020
Figure 8. Hospital Pharmacies Picture
Figure 9. Retail Pharmacies Picture
Figure 10. Online Pharmacies Picture
Figure 11. Global Gestational Diabetes Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Gestational Diabetes Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Gestational Diabetes Treatment Revenue Market Share by Region (2016-2026)
Figure 14. Global Gestational Diabetes Treatment Revenue Market Share by Region in 2020
Figure 15. North America Gestational Diabetes Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Gestational Diabetes Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Gestational Diabetes Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Gestational Diabetes Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Gestational Diabetes Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Gestational Diabetes Treatment Market Drivers
Figure 21. Gestational Diabetes Treatment Market Restraints
Figure 22. Gestational Diabetes Treatment Market Trends
Figure 23. Biocon Limited Recent Developments and Future Plans
Figure 24. Eli Lilly Recent Developments and Future Plans
Figure 25. Novo Nordisk Recent Developments and Future Plans
Figure 26. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Figure 27. Sanofi S.A. Recent Developments and Future Plans
Figure 28. Sun Pharmaceutical Industries Limited Recent Developments and Future Plans
Figure 29. Merck Recent Developments and Future Plans
Figure 30. Novartis Recent Developments and Future Plans
Figure 31. Adocia Recent Developments and Future Plans
Figure 32. Peptron Recent Developments and Future Plans
Figure 33. AstraZeneca plc Recent Developments and Future Plans
Figure 34. Pfizer, Inc Recent Developments and Future Plans
Figure 35. Takeda Pharmaceutical Company Ltd Recent Developments and Future Plans
Figure 36. Abbott Recent Developments and Future Plans
Figure 37. Antares Pharma Recent Developments and Future Plans
Figure 38. INJEX Pharma AG Recent Developments and Future Plans
Figure 39. Daiichi Sankyo Recent Developments and Future Plans
Figure 40. Global Gestational Diabetes Treatment Revenue Share by Players in 2020
Figure 41. Gestational Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players Gestational Diabetes Treatment Revenue Market Share in 2020
Figure 43. Global Top 10 Players Gestational Diabetes Treatment Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global Gestational Diabetes Treatment Revenue Share by Type in 2020
Figure 46. Global Gestational Diabetes Treatment Market Share Forecast by Type (2021-2026)
Figure 47. Global Gestational Diabetes Treatment Revenue Share by Application in 2020
Figure 48. Global Gestational Diabetes Treatment Market Share Forecast by Application (2021-2026)
Figure 49. North America Gestational Diabetes Treatment Sales Market Share by Type (2016-2026)
Figure 50. North America Gestational Diabetes Treatment Sales Market Share by Application (2016-2026)
Figure 51. North America Gestational Diabetes Treatment Revenue Market Share by Country (2016-2026)
Figure 52. United States Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe Gestational Diabetes Treatment Sales Market Share by Type (2016-2026)
Figure 56. Europe Gestational Diabetes Treatment Sales Market Share by Application (2016-2026)
Figure 57. Europe Gestational Diabetes Treatment Revenue Market Share by Country (2016-2026)
Figure 58. Germany Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific Gestational Diabetes Treatment Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific Gestational Diabetes Treatment Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Gestational Diabetes Treatment Revenue Market Share by Region (2016-2026)
Figure 66. China Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America Gestational Diabetes Treatment Sales Market Share by Type (2016-2026)
Figure 73. South America Gestational Diabetes Treatment Sales Market Share by Application (2016-2026)
Figure 74. South America Gestational Diabetes Treatment Revenue Market Share by Country (2016-2026)
Figure 75. Brazil Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa Gestational Diabetes Treatment Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa Gestational Diabetes Treatment Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa Gestational Diabetes Treatment Revenue Market Share by Country (2016-2026)
Figure 80. Turkey Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE Gestational Diabetes Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source
糖尿病治療の世界市場 2019年版：種類別（Ⅰ型糖尿病（青少年発症糖尿病）、Ⅱ型糖尿病（成人発症糖尿病）、妊娠糖尿病）、用途別（研究所、病院） Scope of the Report: The global Diabetic Care market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast g…- スマート糖尿病管理の世界市場 2019年版：種類別（1型糖尿病、2型糖尿病）、用途別（病院、専門糖尿病クリニック、ホーム） Scope of the Report: The global Smart Diabetes Management market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China,…
- 世界の糖尿病管理用連続血糖モニタリング（CGM）システム市場 2021：企業別、地域別、種類・用途別 The Continuous Glucose Monitoring (CGM) System for Diabetes Management market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market playe…
- 糖尿病治療薬市場：世界及び中国市場分析・予測（～2024年） Diabetes Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Diabetes Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Diabetes Drugs manufacturers and is a va…
- タイプ1糖尿病（T1D）市場：世界及び中国市場分析・予測（～2024年） Type 1 Diabetes (T1D) Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Type 1 Diabetes (T1D) industry with a focus on the Chinese market. The report provides key statistics on the market status of the Type 1 Diabetes (T1D) manu…